“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in
Last close As at 25/03/2023
—
— 0.00 (0.00%)
Market capitalisation
—
Based in Vancouver, Renaissance BioScience is a privately held bioengineering company developing proprietary yeast strains for use in the food and beverage, and agriculture industries. Successful in commercially licensing its ‘Generation 1’ technology comprising yeast strains for the food and beverage industry, its focus has shifted to the development of its ‘Generation 2’ technology – yeast strains capable of producing and delivering RNAi for biological crop protection.
Renaissance BioScience is a private bioengineering company developing proprietary yeast strains for use in the food and beverage, healthcare and agriculture industries. It has been successful in commercially licensing its ‘Generation 1’ technology, which comprises yeast strains for use in the food and beverage industry. The primary focus has now shifted to the development of its ‘Generation 2’ technology – yeast strains capable of producing and delivering RNAi – and aims to address challenges in the agriculture and biopharmaceutical industries. Early results indicate that its RNAi solutions could be low-cost, efficacious and non-toxic. As the company is a private entity, we have limited visibility on its financials. However, in November 2021, it successfully closed the balance of its US$5m convertible debenture, proceeds from which have been allocated to advance its RNAi platform.
Get access to the very latest content matched to your personal investment style.
